Decongestant Manufacturing OTC in the US: Market Size, Businesses & Forecast 2026

The over-the-counter (OTC) decongestant manufacturing industry in the United States comprises establishments focused on formulating and packaging nonprescription cold, allergy, and sinus remedies. The industry is currently entering a significant structural transition due to major regulatory revisions targeting widespread active ingredients. While quantitative market totals specific solely to decongestant compounding are not isolated by federal statistical bodies, general pharmaceutical preparation manufacturing (NAICS 325412) recorded total revenues of $177,771,497,000 in 2017 according to the US Census Bureau.

Industry snapshot

Key public data points

Historical & forecast

Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.

What does the Decongestant Manufacturing OTC in the US industry cover?

This industry covers the domestic manufacturing, compounding, and packaging of nonprescription or over-the-counter (OTC) medicines intended to relieve nasal and sinus congestion. These products include oral tablets, caplets, liquids, and topical nasal sprays formulated with vasoconstrictors such as pseudoephedrine, oxymetazoline, or phenylephrine. Production involves strict adherence to chemical compounding standards, final dose molding, and retail packaging formats.

• •Classified under the broader US NAICS code 325412 for Pharmaceutical Preparation Manufacturing.
• •Scope includes single-entity decongestants as well as multi-symptom cold, flu, and allergy formulations.
• •Excludes prescription-strength nasal solutions and uncompounded bulk medicinal chemicals.

Who operates in the industry and how is it structured?

The supply side is divided between multinational consumer healthcare corporations that market major brand-name remedies and large contract manufacturing organizations (CMOs) producing private-label items. Private-label operators formulate store brands for major retail pharmacies, supermarkets, and mass merchandisers. Production requires specialized facilities operating under strict current Good Manufacturing Practices (cGMP).

• •Operators include diverse market tiers from global consumer health brands to specialized private-label compounders.
• •Facilities must register directly with the US Food and Drug Administration (FDA) as drug manufacturing establishments.
• •Significant cost overheads are tied to specialized cleanroom infrastructure, automated tableting, and liquid-filling lines.

What drives demand in the industry?

The consumption of OTC decongestants is primarily driven by seasonal waves of respiratory illnesses and environmental allergens. Seasonal influenza patterns, the prevalence of the common cold, and shifting pollen counts dictate annual order volumes from retail distributors. Additionally, demographic trends like an aging population seeking easily accessible self-care options reinforce stable long-term consumer demand.

• •Epidemiological fluctuations in seasonal cold and influenza virus circulation alter short-term manufacturing quotas.
• •The prevalence of allergic rhinitis triggers demand spikes during spring and autumn pollen seasons.
• •Consumer preference for self-care options over clinical visits supports steady retail market pull.

Who are the notable companies in the industry?

Competition among manufacturers revolves around brand equity, shelf space allocation, and the speed of adjusting to regulatory changes. Multinational consumer product entities compete directly with major domestic private-label suppliers that provide cost-efficient generic alternatives. Operators must maintain diversified product portfolios to hedge against sudden shifts in ingredient compliance.

• •Kenvue Inc. operates as a prominent player, managing the legacy Tylenol and Sudafed product portfolios.
• •Haleon plc maintains a significant footprint through its multi-symptom brand offerings like Theraflu and Robitussin.
• •Procter & Gamble Company manufactures widely distributed congestion products under its Vicks brand portfolio.
• •Bayer AG is active in the domestic market via its allergy and decongestant brands such as Afrin and Claritin-D.

What are the recent trends and outlook?

The primary operational narrative for the industry is the mass reformulation of oral multi-symptom products. Following clinical evidence updates, federal advisory tracks have targeted prominent oral active ingredients, forcing manufacturers to design new pipelines or shift focus back to nasal spray alternatives. This transition is expected to cause widespread label adjustments and supply chain realignments over the coming years.

• •A major shift occurred following an FDA Nonprescription Drugs Advisory Committee finding that oral phenylephrine is ineffective at standard doses.
• •The FDA issued a formal proposal in late 2024 to remove oral phenylephrine from the OTC monograph, accepting public comments through May 2025.
• •Manufacturers are actively reformulating multi-symptom pipelines to utilize alternative active components or expanding topical nasal spray productions.

How is the industry regulated?

Manufacturing is heavily regulated at both the federal and state levels to ensure consumer safety and prevent product diversion. Operators must comply with standard FDA monographs detailing approved active ingredients, dosages, and labeling guidelines. Furthermore, statutory limits on specific precursor chemicals dictate strict behind-the-counter retail controls and specialized production monitoring.

• •Subject to FDA OTC Monograph M012, which governs Cold, Cough, Allergy, Bronchodilator, and Antiasthmatic Drug Products.
• •Enforcement of the federal Combat Methamphetamine Epidemic Act of 2005 regulates the manufacturing and sale of pseudoephedrine-based products.
• •Facilities are subject to unannounced FDA cGMP inspections ensuring compounding sterility, batch uniformity, and trace verification.

Government, statistical and trade sources used for this Claight analysis.

• US Food and Drug Administration (FDA) Proposed Order (Docket No. FDA-2023-N-3531) 2024 ·
• US Food and Drug Administration (FDA) OTC Monograph M012 ·
• US Census Bureau Economic Census 2017 ·
• US Congress - Combat Methamphetamine Epidemic Act of 2005